key: cord-0954057-fypodr9a
authors: Salo, J.; Hagg, M.; Kortelainen, M.; Leino, T.; Saxell, T.; Siikanen, M.; Saaksvuori, L.
title: The indirect effect of mRNA-based Covid-19 vaccination on unvaccinated household members
date: 2021-05-29
journal: nan
DOI: 10.1101/2021.05.27.21257896
sha: b0850bd6034abae0adae4f27e2d16753b9eaaad2
doc_id: 954057
cord_uid: fypodr9a

Abstract: This paper studies the direct and indirect effectiveness of Covid-19 vaccines among vaccinated healthcare workers and their unvaccinated adult household members in a mass vaccine program in Finland. Methods: We used national databases that record all polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infections and mRNA-based (BNT162b2 by Pfizer-BioNTech or mRNA-1273 by Moderna) vaccine doses administered in Finland since the beginning of the epidemic. These data were merged with administrative full population datasets that include information on each person's occupation and unique identifiers for spouses living in the same household. To estimate the direct and indirect effectiveness of mRNA-based vaccines in a household setting, we compared the cumulative incidence of PCR-confirmed SARS-CoV-2 infections between vaccinated and unvaccinated healthcare workers as well as between their unvaccinated spouses. Findings: Our estimates imply indirect effectiveness of 8.7% (95% CI: -28.9 to 35.4) two weeks and 42.9% (95% CI: 22.3 to 58.1) 10 weeks after the first dose. The effectiveness estimates for unvaccinated household members are substantial, but smaller than the direct effect and occur more gradually among unvaccinated household members than among vaccinated individuals. Interpretation: Our results suggest that mRNA-based vaccines do not only prevent SARS-CoV-2 infections among vaccinated individuals but lead to a substantial reduction in infections among unvaccinated household members. The results are consistent with the notion that mRNA-based vaccines affect susceptibility in vaccinated individuals and prevent transmission from vaccinated to unvaccinated individuals.

Our estimates imply indirect effectiveness of 8.7% (95% CI: -28.9 to 35.4) two weeks and 42.9% (95% CI: 22.3 to 58.1) 10 weeks after the first dose. The effectiveness estimates for unvaccinated household members are substantial, but smaller than the direct effect and occur more gradually among unvaccinated household members than among vaccinated individuals.

Our results suggest that mRNA-based vaccines do not only prevent SARS-CoV-2 infections among vaccinated individuals but lead to a substantial reduction in infections among unvaccinated household members. The results are consistent with the notion that mRNA-based vaccines affect susceptibility in vaccinated individuals and prevent transmission from vaccinated to unvaccinated individuals.

Governments around the world are hoping to lift Covid-19 restrictions as vaccination coverage increases.

Simultaneously, many under-vaccinated countries and territories have yet to design and initiate their mass vaccination campaigns. Vaccines have been shown to be effective in reducing SARS-CoV-2 infections among vaccinated individuals both in clinical trials and in nationwide mass vaccination settings. [1] [2] [3] [4] However, there is only little real-world descriptive evidence about the indirect effects of Covid-19 vaccinations. [5] [6] [7] [8] We studied the direct and indirect effectiveness of Covid-19 vaccines in reducing the cumulative risk of infection among vaccinated healthcare workers and their unvaccinated adult household members in a mass vaccine program in Finland. We used national databases that record all polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infections and mRNA-based (BNT162b2 by Pfizer-BioNTech or mRNA-1273 by Moderna) vaccine doses administered in Finland since the beginning of the epidemic.

These data were merged with administrative full population datasets that include information on each person's occupation and unique identifiers for spouses living in the same household. To estimate the direct and indirect effectiveness of mRNA-based vaccines in a household setting, we compared the cumulative incidence of PCR-confirmed SARS-CoV-2 infections between vaccinated and unvaccinated healthcare workers as well as between their unvaccinated spouses (see Supplementary Appendix Table A2 for the covariate balance between the vaccinated and unvaccinated groups). The estimates were adjusted for the state of the epidemic (calendar time fixed effects), age and sex. Figure 1 shows the effectiveness estimates of mRNA-based vaccines for preventing Covid-19 infections among working-age healthcare workers and their spouses between the start of the mass vaccination 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.27.21257896 doi: medRxiv preprint program (December 27, 2020) and March 24, 2021 in Finland. We report estimates by follow-up week after receiving the first dose. We included only persons who had not been infected before the event date.

For unvaccinated individuals, we randomly assigned a placebo event date for vaccine administration during the observation period (see the Supplementary Appendix, Section D, for details). Using this novel approach, we ensure that the vaccine effectiveness estimates are not biased by the changing nature of the epidemic between the treatment and control groups during the follow-up period. Our results remain qualitatively unaltered if we follow all individuals in the control group from the beginning of the mass vaccination program (Supplementary Appendix, Figure A3 ). We used a log-binomial model as it allows direct estimation of vaccine effectiveness in terms of risk reduction.

Our estimates imply a gradual increase in direct effectiveness over time (Figure 1 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The dependent variable is a polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection as recorded in the Finnish National Infectious Diseases Register. Panel A shows our direct effectiveness estimates (relative risk reduction) for vaccinated individuals compared to the control group, which is constructed by randomly assigning a placebo vaccination date for non-vaccinated individuals. Panel B shows the effectiveness estimates (relative risk reduction) for the non-vaccinated spouses (including cohabiting partners) of vaccinated individuals who lived in the same household with the vaccinated person as of December, 31, 2019. See Supplementary Appendix for details on sample restrictions. Coefficients in both panels are estimated using individual-date data collapsed to individual-week data. To construct the relative risk reduction (RRR) estimates, we first run a log-binomial regression model using a vaccination status indicator variable (vaccinated vs. unvaccinated) by the event week (follow-up week after vaccine administration) and transform the obtained estimates into risk ratio coefficients. We then compute the relative risk reduction using the formula RRR = 1 -risk ratio. The solid black dots show relative risk reduction by week after receiving the first dose of mRNA-based vaccination. Error bars denote the 95% confidence intervals clustered at the individual level using endpoint transformation of originally estimated confidence intervals.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.27.21257896 doi: medRxiv preprint

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey

Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households

Impact of vaccination on household transmission of SARS-COV-2 in England

SARS-CoV-2 infection risk among unvaccinated is negatively associated with community-level vaccination rates

Indirect Protection by Reducing Transmission: Ending the Pandemic with SARS-CoV-2 Vaccination. Open Forum Infectious Diseases 2021

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine